Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout t... Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Our lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We are developing obexelimab for patients in several autoimmune diseases. Mehr anzeigen
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy...
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas...
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in...
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the...
ProShares, a premier provider of ETFs, announced today forward and reverse share splits on 20 of its ETFs. The splits will not change the total value of a shareholder's investment...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.85 | -8.62068965517 | 9.86 | 10.2606 | 7.79 | 220467 | 8.96415952 | CS |
| 4 | -1.74 | -16.1860465116 | 10.75 | 11.3927 | 7.79 | 539911 | 9.70995813 | CS |
| 12 | -8 | -47.0311581423 | 17.01 | 26.2508 | 7.79 | 320178 | 12.41878333 | CS |
| 26 | -1.0104 | -10.0834298032 | 10.0204 | 26.2508 | 7.79 | 178028 | 13.45563223 | CS |
| 52 | -1.0104 | -10.0834298032 | 10.0204 | 26.2508 | 7.79 | 90427 | 13.45563223 | CS |
| 156 | -1.0104 | -10.0834298032 | 10.0204 | 26.2508 | 7.79 | 30182 | 13.45563223 | CS |
| 260 | -0.054 | -0.595763459841 | 9.064 | 26.2508 | 7.79 | 21934 | 13.21197339 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
